A Comprehensive Clinical and Pharmacological Review of Biosynthetic Glucagon: From Molecular Mechanisms to Modern Therapeutic Formulations

Executive Summary

Glucagon, a critical counter-regulatory hormone to insulin, serves as a life-saving intervention for severe hypoglycemia. The advent of biosynthetic glucagon, produced via recombinant DNA technology or chemical peptide synthesis, marked a significant departure from historically impure animal-derived preparations. This report provides an exhaustive analysis of biosynthetic glucagon, examining its biochemical structure, physiological function, molecular mechanism of action, and pharmacokinetic profile. A central theme is the evolution of its manufacturing, which has led to a critical regulatory and market divergence between innovator products derived from recombinant DNA and generic versions produced by chemical synthesis.

The therapeutic landscape for severe hypoglycemia has been fundamentally transformed in recent years. This transformation is characterized by a paradigm shift away from cumbersome, multi-step reconstitution emergency kits, which are prone to user error in high-stress situations, toward a new generation of stable, ready-to-use (RTU) formulations. This report details the clinical profiles of these innovative products, including the intranasal powder Baqsimi, the liquid injectable auto-injector Gvoke, and the glucagon analog dasiglucagon, Zegalogue.

A comprehensive comparative analysis, based on pivotal clinical trial data and indirect treatment comparisons, reveals that while all modern RTU formulations demonstrate high rates of treatment success, they possess nuanced differences in their pharmacodynamic profiles and routes of administration. Notably, distinctions in the peak glucose concentration achieved may have clinical implications for preventing rebound hyperglycemia, aligning with modern diabetes management principles. The significant improvement in usability and the reduction in administration errors offered by RTU products have led to their recommendation as the new standard of care by major clinical bodies.

Finally, this report explores the future perspectives of glucagon therapy. The inherent physicochemical challenges of the native molecule, namely its poor stability in aqueous solutions, have been a primary driver of innovation. Overcoming this final barrier to create an ultrastable glucagon analog suitable for continuous infusion remains the ultimate goal, a development that would enable the widespread implementation of bi-hormonal artificial pancreas systems and revolutionize the proactive prevention of hypoglycemia in diabetes management.

---

Section 1: The Biochemical and Physiological Profile of Human Glucagon

1.1. Molecular Structure and Physicochemical Properties

Glucagon is a single-chain polypeptide hormone that plays a central role in carbohydrate metabolism.[1] It is composed of 29 amino acids arranged in a specific primary sequence: His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr.[2] This precise structure gives the molecule a molecular formula of

C153​H225​N43​O49​S and a corresponding molecular weight of approximately 3483 Daltons.[3] One International Unit of glucagon is equivalent to 1 mg.[5]

Despite its critical physiological function, the glucagon peptide presents significant physicochemical challenges that have historically constrained its pharmaceutical development. The molecule has poor solubility in aqueous solutions at or near physiological pH (around 7.4).[6] It can only be solubilized at clinically relevant concentrations under acidic (pH 2.5-3.5) or basic conditions.[4] Even under these conditions, it is chemically unstable and prone to degradation.[6] A more formidable challenge is its high propensity for self-association into trimeric structures and subsequent fibrillation to form insoluble amyloid aggregates.[7] This physical instability in a liquid state is the primary reason that traditional glucagon formulations have been supplied as a lyophilized (freeze-dried) powder that must be reconstituted with an acidic diluent immediately prior to administration.[7] Recent research has explored strategies like amino acid substitution and glycosylation to overcome these inherent limitations.[6]

1.2. The Proglucagon Gene and Tissue-Specific Post-Translational Processing

Human glucagon is not directly encoded by its own gene but is instead a product of the post-translational processing of a larger precursor molecule, proglucagon. The preproglucagon gene is expressed in several distinct tissues, most notably the alpha cells of the pancreatic islets, the enteroendocrine L-cells of the intestine, and specific neurons in the brainstem and hypothalamus.[11] The processing of the proglucagon peptide is highly tissue-specific, dictated by the differential expression of enzymes known as prohormone convertases (PCs). This leads to the generation of a family of distinct but related peptides with often opposing physiological functions.[11]

In the alpha cells of the pancreas, the prohormone convertase 2 (PC2) enzyme is predominantly expressed. PC2 cleaves the proglucagon precursor to yield three main products: glicentin-related pancreatic polypeptide (GRPP), the 29-amino acid glucagon hormone, and a large C-terminal fragment known as the major proglucagon fragment (MPGF).[12] In contrast, in the intestinal L-cells and the brain, the prohormone convertase 1 (also known as PC1/3) is the primary processing enzyme. PC1/3 cleaves proglucagon at different sites, resulting in the production of glicentin (which can be further processed to GRPP and oxyntomodulin), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2).[11]

This differential processing represents a remarkable example of biological efficiency. A single gene, proglucagon, serves as the blueprint for hormones with diametrically opposed effects on glucose homeostasis. Glucagon, produced in the pancreas, is a potent hyperglycemic agent that raises blood glucose. Conversely, GLP-1, produced in the gut in response to nutrient intake, is a powerful incretin hormone that stimulates insulin secretion and thus lowers blood glucose.[11] This elegant system allows the body to deploy the appropriate hormonal response based on metabolic context—releasing glucagon during fasting or hypoglycemia when the pancreas senses low systemic glucose, and releasing GLP-1 after a meal when the gut senses nutrient arrival. This pathway has become a major focus for pharmaceutical development, leading to GLP-1 receptor agonists for diabetes and obesity treatment.

1.3. Endogenous Secretion and Regulation by Pancreatic Islet Cells

Glucagon is synthesized and secreted from the alpha cells, which comprise approximately 10% of the cellular volume of the pancreatic islets of Langerhans in humans.[11] The secretion of glucagon is tightly regulated by a complex interplay of nutritional, hormonal, and neural signals. The most potent physiological stimulus for glucagon release is hypoglycemia (low blood glucose).[16] Conversely, its secretion is strongly inhibited by hyperglycemia (high blood glucose), insulin, and another islet hormone, somatostatin.[14] Other factors that stimulate glucagon release include the ingestion of protein-rich meals (specifically, amino acids), prolonged fasting, exercise, and the gut hormone glucose-dependent insulinotropic peptide (GIP).[16]

The intricate microanatomy of the pancreatic islet plays a crucial role in this regulation. In humans, alpha cells are interspersed with insulin-secreting beta cells (which make up ~80% of the islet).[11] The unique islet vasculature, resembling a renal glomerulus, typically directs blood flow from the central beta cells towards the more peripheral alpha cells.[11] This arrangement exposes the alpha cells to very high local concentrations of insulin, which exerts a powerful tonic inhibitory (paracrine) effect on glucagon secretion.[11] The mechanism for glucagon release during hypoglycemia is therefore multifactorial, involving: (1) a direct stimulatory effect of low glucose on the alpha cell itself, (2) the withdrawal of the potent inhibitory signal from adjacent beta cells as insulin secretion falls, and (3) stimulatory input from the autonomic nervous system.[11]

1.4. The Role of Glucagon in Systemic Glucose Homeostasis

Glucagon's primary physiological role is to function as the body's main counter-regulatory hormone to insulin, defending against hypoglycemia and ensuring a stable supply of glucose, particularly for the brain.[14] During periods of fasting, exercise, or other metabolic stress, glucagon secretion increases, signaling the liver to produce and release glucose into the bloodstream, thereby maintaining euglycemia.[11]

The balance between insulin and glucagon is fundamental to metabolic health. The "bihormonal regulation" theory posits that diabetes is not merely a disease of insulin deficiency but also one of glucagon excess.[17] In individuals with type 1 diabetes, the loss of insulin production also leads to the loss of its paracrine inhibition of glucagon, resulting in inappropriately high glucagon levels (hyperglucagonemia). This excess glucagon drives hepatic glucose overproduction and exacerbates hyperglycemia; it also promotes ketogenesis, contributing to the development of diabetic ketoacidosis (DKA).[11] Similarly, fasting hyperglucagonemia is an early pathological feature in the development of type 2 diabetes.[14] This dual-hormone dysregulation underscores the importance of glucagon as a therapeutic target and explains why therapies that inhibit glucagon secretion, such as GLP-1 receptor agonists, are effective in managing diabetes.[11]

---

Section 2: Pharmacodynamics: The Molecular Mechanism of Action

2.1. The Glucagon Receptor (GCGR) and G-Protein Signaling Cascade

The biological effects of glucagon are initiated by its binding to a specific cell surface receptor, the glucagon receptor (GCGR). The GCGR is a member of the Class B family of G-protein-coupled receptors (GPCRs) and is predominantly expressed on the surface of hepatocytes (liver cells), with lower levels of expression in the kidney, heart, adipose tissue, and certain regions of the brain.[17]

Upon binding of glucagon to the extracellular domain of the GCGR, the receptor undergoes a conformational change that activates its associated intracellular heterotrimeric G-proteins. The GCGR couples to at least two distinct G-protein subtypes: Gsα​ and Gq​.[18] This dual signaling capacity allows glucagon to elicit a robust and multifaceted response within the target cell.

Activation of the Gsα​ subunit stimulates the membrane-bound enzyme adenylate cyclase. This enzyme catalyzes the conversion of adenosine triphosphate (ATP) to the second messenger cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP concentration leads to the activation of Protein Kinase A (PKA).[18] The PKA pathway is the principal mediator of glucagon's metabolic effects in the liver.

Simultaneously, activation of the Gq​ subunit stimulates the enzyme phospholipase C. This enzyme cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2​) into two second messengers: inositol 1,4,5-triphosphate (IP3​) and diacylglycerol (DAG). IP3​ diffuses through the cytoplasm and binds to receptors on the endoplasmic reticulum, triggering the release of stored intracellular calcium (Ca2+).[18] The rise in intracellular calcium further contributes to the cellular response initiated by glucagon.

2.2. Primary Hepatic Effects: Glycogenolysis and Gluconeogenesis

The liver is the primary target organ for glucagon, and its effects are aimed at increasing hepatic glucose output.[11] Glucagon achieves this through the coordinate regulation of four key metabolic pathways. The activation of PKA by cAMP initiates a phosphorylation cascade that rapidly stimulates glucose production. PKA phosphorylates and activates another enzyme, glycogen phosphorylase kinase. This kinase, in turn, phosphorylates and activates glycogen phosphorylase, the rate-limiting enzyme in glycogenolysis.[1] Activated glycogen phosphorylase catalyzes the breakdown of stored glycogen into glucose-1-phosphate, which is then converted to glucose-6-phosphate and finally to free glucose for release into the bloodstream.[1] This stimulation of glycogenolysis is the most rapid and critical mechanism by which glucagon counters acute hypoglycemia.[16]

In addition to mobilizing stored glucose, glucagon also promotes the de novo synthesis of glucose from non-carbohydrate precursors, a process known as gluconeogenesis.[1] This is a more sustained response that becomes crucial during prolonged fasting when glycogen stores are depleted. Glucagon stimulates gluconeogenesis by regulating the transcription and activity of key enzymes in the pathway.

To ensure a net increase in glucose output, glucagon simultaneously inhibits the opposing metabolic pathways. It inhibits glycolysis (the breakdown of glucose for energy within the liver) and glycogenesis (the synthesis of glycogen for storage), preventing the newly produced glucose from being immediately consumed or re-stored by the liver.[1]

The efficacy of glucagon is therefore critically dependent on the availability of hepatic glycogen stores. Its hyperglycemic effect is enhanced when liver glycogen levels are high and significantly diminished in conditions where these stores are low, such as prolonged fasting, adrenal insufficiency, or certain liver diseases like cirrhosis.[16]

2.3. Secondary Metabolic Effects: Ketogenesis and Lipolysis

Beyond its primary role in glucose regulation, glucagon also influences lipid and ketone body metabolism, contributing to overall energy homeostasis, especially during periods of energy scarcity.[16] In the liver, glucagon signaling shifts fatty acid metabolism away from storage and towards energy production. It enhances the breakdown of fatty acids into acetyl-CoA via beta-oxidation.[16] These acetyl-CoA molecules can then either enter the tricarboxylic acid (TCA) cycle to generate ATP or be converted into ketone bodies (acetoacetate and beta-hydroxybutyrate) through a process called ketogenesis, which is also stimulated by glucagon.[1] Ketone bodies serve as a vital alternative energy source for extrahepatic tissues, including the brain, during prolonged fasting or in states of insulin deficiency.[1] Furthermore, glucagon inhibits

de novo lipogenesis by inactivating the key enzyme that catalyzes the first step in fatty acid synthesis.[16]

Glucagon also acts on adipose (fat) tissue, stimulating the breakdown of stored triglycerides (lipolysis) into free fatty acids and glycerol, which are then released into the circulation to be used as fuel by other tissues.[1]

2.4. Extra-Hepatic Actions: Gastrointestinal Smooth Muscle Relaxation

Independent of its metabolic actions, glucagon exerts a potent spasmolytic effect on the smooth muscle of the gastrointestinal (GI) tract. It causes relaxation of the stomach, duodenum, small bowel, and colon.[3] This effect is harnessed clinically for its secondary indication as a diagnostic aid. By temporarily inhibiting GI motility, glucagon facilitates various radiological and endoscopic procedures, such as endoscopic retrograde cholangiopancreatography (ERCP), by providing a clearer and more stable field of view.[1]

The interplay between insulin and glucagon signaling within the hepatocyte provides a critical physiological failsafe mechanism. Under normal or hyperglycemic conditions, insulin signaling is dominant. It promotes glucose uptake and storage while actively suppressing the pathways stimulated by glucagon. However, during a hypoglycemic crisis, this balance shifts dramatically. Glucagon signaling becomes predominant and is capable of overriding the hepatic effects of insulin, even in the presence of high insulin concentrations, as seen in cases of insulin overdose.[21] This physiological switch ensures that the body can mount a robust counter-regulatory response to raise blood glucose levels when it is most needed. This principle is not merely a biochemical curiosity; it is the fundamental reason why exogenous glucagon is an effective rescue therapy for severe insulin-induced hypoglycemia and is the conceptual basis for the development of novel glucagon-insulin co-formulations.[21]

---

Section 3: Pharmacokinetics and Metabolism

3.1. Absorption Profiles Across Administration Routes (Parenteral, Intranasal)

The pharmacokinetic profile of glucagon varies significantly depending on its route of administration, which in turn influences its onset of action in an emergency setting.

Parenteral Administration (Intramuscular, Subcutaneous, Intravenous):

• Intramuscular (IM) Injection: When administered as a 1 mg dose, glucagon is rapidly absorbed. Peak plasma concentrations (Cmax​) are typically reached in approximately 13 to 26 minutes.[5]
• Subcutaneous (Sub-Q) Injection: Absorption from the subcutaneous tissue is slightly slower than from muscle. Following a 1 mg Sub-Q dose, Cmax​ is generally achieved in about 20 to 32 minutes.[5] In a study of a 1 mg Sub-Q dose, the mean peak glucose concentration of 136 mg/dL was observed at 30 minutes post-injection.[5]
• Intravenous (IV) Injection: As expected, IV administration bypasses the absorption phase entirely, providing the most rapid delivery into the systemic circulation and the fastest onset of action. This route is typically reserved for use by healthcare professionals in a clinical setting.[4]

Intranasal Administration:

• Nasal Powder (Baqsimi): The intranasal formulation is designed for passive absorption across the nasal mucosa. The pharmacokinetic profile shows a slightly delayed peak compared to parenteral routes, with the half-life of the nasal powder being approximately 35 minutes.[18] Importantly, clinical studies have demonstrated that the absorption and subsequent pharmacodynamic effect are not meaningfully impacted by conditions such as the common cold, nasal congestion, or the use of nasal decongestant sprays, ensuring its reliability in real-world scenarios.[25]

3.2. Distribution, Metabolism, and Systemic Clearance

Once in the systemic circulation, glucagon exhibits a small volume of distribution, with a mean of approximately 0.25 L/kg, and is not significantly bound to plasma proteins.[5] This indicates that the hormone is primarily distributed within the vascular and interstitial compartments rather than accumulating in tissues.

Glucagon is a peptide and is therefore subject to extensive and rapid proteolytic degradation. It is metabolized into smaller, inactive polypeptides and constituent amino acids primarily in the liver and the kidneys, with each organ being responsible for clearing approximately 30% of the hormone from circulation.[5] The plasma also contains enzymes that contribute to its breakdown.[18] This rapid and widespread metabolism results in a moderate systemic clearance of about 13.5 mL/min/kg.[5]

3.3. Half-Life and Duration of Action of Different Formulations

The extensive metabolism of glucagon results in a very short biological half-life.

• For an intravenous dose, the half-life ranges from 8 to 18 minutes.[5]
• For an intramuscular dose, the half-life is approximately 26 minutes.[18]
• For a subcutaneous auto-injector dose (Gvoke), the half-life is about 32 minutes.[18]
• For the nasal powder (Baqsimi), the half-life is approximately 35 minutes.[18]

While the plasma half-life is short, the pharmacodynamic effect—the rise in blood glucose—is more prolonged but still transient. The hyperglycemic action of a single rescue dose typically lasts for about 90 minutes.[27] This limited duration of action is a critical clinical consideration. It underscores the necessity of administering a source of oral carbohydrates to the patient as soon as they regain consciousness and are able to swallow. This follow-up action is essential to replenish the hepatic glycogen stores that were depleted by the glucagon and to prevent a recurrence of hypoglycemia once the effect of the rescue dose wanes.[27]

The pharmacokinetic profile of glucagon can be viewed as a double-edged sword. Its rapid clearance and short half-life are highly advantageous for an emergency rescue medication. This profile minimizes the risk of causing prolonged or excessive iatrogenic hyperglycemia, allowing the patient's own physiological systems or subsequent food intake to re-establish control once the immediate crisis is resolved. However, this same characteristic makes native glucagon entirely unsuitable for chronic or prophylactic applications. The development of a bi-hormonal artificial pancreas, or closed-loop system, which aims to prevent hypoglycemia by administering continuous or micro-bolus infusions of glucagon, is contingent on overcoming this limitation. The instability and short duration of action of native glucagon have been the primary impetus for a parallel stream of research focused on creating novel, ultrastable, long-acting glucagon analogs specifically for use in such automated systems.[29] Thus, the very property that makes glucagon an excellent rescue drug is the principal barrier to its use in next-generation prophylactic technologies.

---

Section 4: The Advent of Biosynthetic Glucagon: Manufacturing and Production

4.1. Defining "Biosynthetic": A Departure from Animal-Derived Preparations

The term "biosynthetic glucagon" broadly refers to any glucagon product that is manufactured using modern biotechnological or chemical methods to be structurally identical to human glucagon. This designation distinguishes it from early glucagon preparations, which were obtained through extraction from the pancreases of animals, typically cows and pigs.[2] The extraction process was inefficient, yielding only a fraction of the available hormone, and resulted in an inhomogeneous final product that was often contaminated with other pancreatic proteins, such as insulin, and carried a risk of inducing allergic reactions in patients.[2] The development of biosynthetic methods revolutionized glucagon production, enabling the creation of a highly pure, human-sequence hormone, thereby improving safety and consistency. Within the umbrella of "biosynthetic," two principal and distinct manufacturing technologies have emerged: recombinant DNA technology and chemical peptide synthesis.[31]

4.2. Recombinant DNA (rDNA) Technology in Yeast and Bacterial Systems

Recombinant DNA (rDNA) technology is a biological manufacturing process that utilizes genetically engineered host organisms to produce a target protein. For glucagon, this process involves inserting the synthetic or cDNA-derived gene encoding human glucagon into a replicable expression vehicle, such as a plasmid.[2] This recombinant plasmid is then introduced into a host microorganism. The most common host for commercial glucagon production is the yeast strain

Saccharomyces cerevisiae [2], though bacterial systems like

Escherichia coli have also been used.[37]

The transformed host cells are cultivated in large-scale industrial fermenters under controlled conditions that promote cell growth and expression of the glucagon protein.[38] After fermentation, the cells are harvested, and the glucagon protein is extracted and subjected to extensive purification procedures to remove host cell-derived proteins and other contaminants.[38] This rDNA method has been the established process for producing the innovator, or reference listed drug (RLD), versions of glucagon, including Eli Lilly's Glucagon for Injection and Novo Nordisk's GlucaGen.[31]

4.3. Synthetic Production via Solid-Phase Peptide Synthesis (SPPS)

In contrast to the biological process of rDNA technology, synthetic production involves the de novo chemical construction of the glucagon peptide. The predominant method is Solid-Phase Peptide Synthesis (SPPS).[30] In this process, the 29-amino acid chain is assembled sequentially. The first amino acid is chemically anchored to an insoluble solid polymer resin. The peptide is then elongated one amino acid at a time through a series of repeated cycles of deprotection and coupling reactions.[34]

The synthesis of a long peptide like glucagon via SPPS is chemically challenging due to the potential for inter- and intra-molecular hydrogen bonding of the growing peptide chain on the resin. This can lead to aggregation, which hinders subsequent coupling reactions and results in the formation of truncated sequences and other impurities, reducing both the yield and purity of the final product.[30] To overcome these difficulties, advanced chemical strategies are employed, such as conducting reactions at higher temperatures or using "pseudoproline dipeptides" as temporary protecting groups to disrupt secondary structure formation and maintain coupling efficiency.[30] After the full peptide chain is assembled, it is cleaved from the resin and undergoes purification, typically using high-performance liquid chromatography (HPLC).[42] This chemical synthesis method is used to manufacture the first FDA-approved generic versions of glucagon for injection, such as those from Amphastar Pharmaceuticals and Fresenius Kabi.[1]

4.4. Comparative Analysis: Purity, Impurity Profiles, and Regulatory Implications

The two distinct manufacturing processes—one biological, one chemical—inherently lead to different impurity profiles in the final active pharmaceutical ingredient (API). Recombinant products may contain process-related impurities such as host cell-derived proteins or DNA, which must be carefully monitored and removed.[31] Synthetic products, on the other hand, may contain impurities related to the chemical process, such as truncated peptides, deletion sequences, or chemically modified amino acids.[30]

The approval by the U.S. Food and Drug Administration (FDA) of a synthetic generic glucagon as an equivalent to the recombinant RLD marked a pivotal moment in pharmaceutical regulation. Historically, for complex biological molecules, the manufacturing process was considered integral to the final product's identity—the "process is the product." This approval signaled a significant evolution in regulatory science. The FDA determined that "sameness" between a synthetic peptide and a recombinant peptide could be adequately established through a battery of advanced analytical methods. This requires demonstrating equivalence in physicochemical properties, primary and secondary structures, aggregation states, and oligomerization, supplemented by biological assays to confirm equivalent potency.[31] Furthermore, any new impurities present in the synthetic product that are not in the RLD must be thoroughly characterized and assessed for potential immunogenicity using non-clinical assays.[31] This landmark decision effectively decouples the identity of a therapeutic peptide from its method of origin, setting a clear regulatory pathway for future generic versions of other complex peptide drugs.

Perhaps counterintuitively, direct comparative studies have challenged the assumption that biological production is inherently superior for creating a "natural" hormone. An analysis using ultra-performance liquid chromatography (UPLC) to compare the purity and stability of a synthetic generic glucagon with the recombinant RLD found that the synthetic product was not only comparable but often superior. Across all tested storage and temperature conditions, the synthetic glucagon exhibited a higher average purity (92.8–99.3%) compared to the recombinant drug (70.3–91.7%) and was found to have a lower number of total impurity peaks.[34] This empirical evidence suggests that for a moderately sized peptide like glucagon, the precision and control afforded by modern chemical synthesis can yield a final product with higher purity than that achieved through recombinant expression in a living organism. This has significant implications for future manufacturing strategies for therapeutic peptides.

---

Section 5: Clinical Indications and Therapeutic Applications

5.1. Primary Indication: Emergency Management of Severe Hypoglycemia

The primary and most critical clinical indication for biosynthetic glucagon is the emergency treatment of severe hypoglycemia in both pediatric and adult patients with diabetes mellitus.[1] Severe hypoglycemia is defined as a hypoglycemic event characterized by altered mental and/or physical status requiring assistance from another person for recovery.[48] In such situations, the patient is often unable to safely ingest oral carbohydrates due to confusion, disorientation, or unconsciousness. Glucagon provides a life-saving intervention by rapidly raising blood glucose levels through the mobilization of hepatic glycogen stores, allowing for recovery until oral carbohydrates can be administered.[1] It is a cornerstone of emergency care for individuals treated with insulin or other medications that can cause severe hypoglycemia.

5.2. Diagnostic Application in Gastrointestinal Radiology

A well-established secondary indication for glucagon is its use as a diagnostic aid during radiologic examinations of the GI tract.[1] This application leverages glucagon's pharmacodynamic effect of inducing smooth muscle relaxation in the stomach, duodenum, small bowel, and colon.[8] The temporary inhibition of intestinal motility, or spasmolytic effect, creates a more stable environment for imaging, which can be advantageous for procedures such as barium studies or endoscopic retrograde cholangiopancreatography (ERCP).[8] This allows for improved visualization and can increase the success rate of the diagnostic procedure.

5.3. Emerging and Off-Label Uses: Toxin-Induced Cardiotoxicity and Anaphylaxis

Beyond its approved indications, glucagon is utilized off-label in several acute care and emergency medicine settings, primarily in toxicology.

• Beta-Blocker and Calcium-Channel Blocker Overdose: Glucagon is considered a key antidote in the management of severe cardiotoxicity resulting from an overdose of beta-blockers or calcium-channel blockers.[8] In these poisonings, patients present with profound bradycardia and hypotension. The therapeutic action of glucagon in this context is a direct extension of its molecular mechanism. Beta-blockers antagonize β-adrenergic receptors in the heart, which normally increase heart rate and contractility via a G-protein/adenylate cyclase/cAMP signaling pathway. Glucagon binds to its own distinct receptor on myocardial cells, which also couples to adenylate cyclase and stimulates cAMP production.[5] By administering high doses of glucagon, clinicians can effectively bypass the blocked β-adrenergic receptors and activate the same downstream signaling pathway, leading to a positive inotropic (increased contractility) and chronotropic (increased heart rate) effect that can reverse the toxicity.[8]
• Anaphylaxis: In rare cases, patients experiencing anaphylaxis who are on chronic beta-blocker therapy may be resistant to the effects of epinephrine. In this specific situation of refractory hypotension, intravenous glucagon may be administered as an adjunctive therapy to help stabilize blood pressure.[8]
• Impacted Esophageal Food Bolus: Glucagon is sometimes used in an attempt to relieve an impacted food bolus in the esophagus, colloquially known as "steakhouse syndrome." The rationale is that glucagon's smooth muscle relaxant properties may help relax the lower esophageal sphincter, allowing the bolus to pass into the stomach.[8] However, the evidence supporting its effectiveness for this condition is limited, and while its safety profile makes it an acceptable option, it should not delay more definitive treatments.[8]

---

Section 6: The Evolving Landscape of Commercial Glucagon Formulations

6.1. Legacy Formulations: The Challenges of Reconstitution Kits

For decades, the only available form of emergency glucagon was a reconstitution kit. Prominent examples include the Glucagon Emergency Kit from Eli Lilly and the GlucaGen HypoKit from Novo Nordisk.[7] These kits contain two primary components: a vial of lyophilized (freeze-dried) glucagon powder and a separate syringe pre-filled with a sterile diluent.[7] The reason for this formulation is the inherent physical instability of the glucagon peptide in an aqueous solution, where it rapidly forms amyloid fibrils and loses its biological activity.[7]

While effective when used correctly, the primary and significant drawback of these legacy kits is the complex, multi-step preparation process that must be performed by a caregiver—often a family member or friend without medical training—during a high-stress, time-critical emergency.[10] The process involves injecting the diluent into the powder vial, swirling to dissolve the powder, drawing the solution back into the syringe, and then administering the injection. This procedure is notoriously prone to user error, which can lead to delays in treatment or complete administration failure, with potentially devastating consequences for the patient.[26]

6.2. Ready-to-Use Liquid Injectables: Gvoke (Glucagon) and Zegalogue (Dasiglucagon)

The recognized limitations of reconstitution kits spurred the development of stable, ready-to-use (RTU) liquid formulations, which represent a major therapeutic advancement.

• Gvoke (glucagon): Approved by the FDA in 2019, Gvoke was the first room-temperature stable, premixed liquid glucagon injection.[50] Developed by Xeris Pharmaceuticals, it overcomes the peptide's instability by using a proprietary nonaqueous, aprotic polar solvent formulation technology.[52] This innovation allows the glucagon to remain stable in solution for an extended shelf life. Gvoke is available in several user-friendly formats: a pre-filled syringe (PFS), an auto-injector (HypoPen) with a concealed needle, and a traditional vial and syringe kit for professional use.[27]
• Zegalogue (dasiglucagon): Approved by the FDA in 2021, Zegalogue is a glucagon analog developed by Zealand Pharma.[56] Instead of altering the solvent, this product alters the hormone itself. Dasiglucagon features seven amino acid substitutions in the glucagon sequence, which were specifically designed to enhance its physicochemical properties, increasing its solubility and preventing fibrillation in a standard aqueous solution.[9] This allows it to be formulated as a stable, ready-to-use liquid. Zegalogue is available as a pre-filled syringe and an auto-injector.[56]

6.3. Needle-Free Administration: Baqsimi Intranasal Glucagon Powder

Also approved by the FDA in 2019, Baqsimi, developed by Eli Lilly, was the first non-injectable, needle-free glucagon rescue treatment.[57] It is a single-use, disposable device that delivers a 3 mg dose of dry glucagon powder into one nostril.[10] The powder is absorbed passively across the nasal mucosa into the bloodstream. A key feature is that it does not require the patient to actively inhale or coordinate their breathing, making it simple to administer to a disoriented or even unconscious individual.[26] This formulation completely eliminates the need for needles and the associated fear or hesitation, representing a significant step forward in simplifying emergency glucagon administration.

Table 1: Comparative Profile of Commercial Glucagon Preparations

Product Name (Brand)	Manufacturer	Active Ingredient	Formulation	Delivery Device	Administration Route	Preparation Required	Approved Age	Standard Dose(s)
Glucagon Emergency Kit	Eli Lilly, Fresenius Kabi	Glucagon (rDNA or synthetic)	Lyophilized Powder	Vial & Syringe Kit	IM, Sub-Q, IV	Yes (Reconstitution)	All ages	1 mg (adults/peds >20-25 kg); 0.5 mg (peds <20-25 kg)
GlucaGen HypoKit	Novo Nordisk	Glucagon (rDNA)	Lyophilized Powder	Vial & Syringe Kit	IM, Sub-Q, IV	Yes (Reconstitution)	All ages	1 mg (adults/peds >25 kg); 0.5 mg (peds <25 kg)
Baqsimi	Eli Lilly	Glucagon (rDNA)	Nasal Powder	Single-Use Nasal Device	Intranasal	No (Ready-to-Use)	≥4 years	3 mg (fixed dose)
Gvoke	Xeris Pharmaceuticals	Glucagon (rDNA)	Liquid Solution	Auto-Injector (HypoPen), Pre-filled Syringe (PFS), Kit	Sub-Q	No (Ready-to-Use)	≥2 years	1 mg (adults/peds ≥45 kg); 0.5 mg (peds <45 kg)
Zegalogue	Zealand Pharma / Novo Nordisk	Dasiglucagon (Analog)	Liquid Solution	Auto-Injector, Pre-filled Syringe	Sub-Q	No (Ready-to-Use)	≥6 years	0.6 mg (fixed dose)

Data compiled from sources:.[1]

---

Section 7: Dosage Regimens and Administration Guidelines

7.1. Dosing in Adult Populations for Hypoglycemia and Diagnostic Use

Treatment of Severe Hypoglycemia:

For adult patients (and pediatric patients weighing more than 25 kg or aged 6 years and older, depending on the product), the standard dose of injectable glucagon is 1 mg.4 This dose is administered via subcutaneous, intramuscular, or intravenous injection. For the intranasal formulation, Baqsimi, the recommended adult dose is a single 3 mg actuation into one nostril.19 For the glucagon analog, Zegalogue, the standard adult dose is 0.6 mg via subcutaneous injection. In the event of an inadequate response, a second dose of the same strength may be administered after 15 minutes while awaiting the arrival of emergency medical services.4

Use as a Diagnostic Aid:

When used to inhibit GI motility for radiological examinations, the dosage for adults varies depending on the targeted organ and the desired onset and duration of effect. Doses typically range from 0.2 mg to 2 mg, administered intravenously or intramuscularly.4 For example, relaxation of the stomach may require a higher dose (e.g., 0.5 mg IV or 2 mg IM) compared to the small bowel (e.g., 0.2-0.5 mg IV or 1 mg IM).4

7.2. Pediatric Dosing Considerations: Weight-Based and Age-Based Protocols

Dosing in the pediatric population is more nuanced and is typically stratified by the patient's age and/or body weight to ensure safety and efficacy.

• Traditional Reconstitution Kits (Glucagon Emergency Kit, GlucaGen): The standard pediatric dosing is bifurcated. For children weighing less than 20-25 kg (approximately <6 years of age), the recommended dose is 0.5 mg (half the adult dose). For children weighing 20-25 kg or more (approximately ≥6 years of age), the full adult dose of 1 mg is used.[4]
• Gvoke (Liquid Glucagon): Gvoke, approved for children aged 2 years and older, uses a specific weight-based protocol for younger children. The dose is 0.5 mg for pediatric patients aged 2 to under 12 years who weigh less than 45 kg. For those in the same age group weighing 45 kg or more, and for all pediatric patients aged 12 and older, the standard 1 mg dose is recommended.[51]
• Baqsimi (Nasal Powder): Baqsimi simplifies pediatric dosing significantly. It is approved for children aged 4 years and older, and a single, fixed 3 mg dose is used for all patients in this age group, regardless of weight.[19]
• Zegalogue (Dasiglucagon): Zegalogue is approved for children aged 6 years and older. It utilizes a single, fixed 0.6 mg dose for all patients in this approved age range.[57]

7.3. Emergency Administration Protocols for Caregivers and First Responders

Given that severe hypoglycemia requires assistance from others, proper education of caregivers, family members, and friends is paramount. The administration protocol involves several critical steps that must be followed to ensure patient safety and effective recovery.

Immediate Actions:

1. Administer Glucagon: The prescribed glucagon product should be administered as soon as severe hypoglycemia is recognized. For injectable products, common sites are the outer thigh, upper arm, or buttocks.[4] For Baqsimi, the device tip is inserted into one nostril and the plunger is fully depressed.[60]
2. Call for Emergency Assistance: Immediately after administering the dose, the caregiver must call for emergency medical help (e.g., 911 in the United States).[60] Glucagon is a temporary rescue measure, and the patient requires professional medical evaluation.

Post-Administration Care:

1. Position the Patient: A very common side effect of glucagon is nausea and vomiting. To prevent aspiration and choking, the patient should be immediately turned onto their side into the recovery position, especially if they are unconscious.[27]
2. Monitor for Response: The patient should typically regain consciousness within 15 minutes. If there is no response after this time, a second dose may be administered if available and as directed by the product's instructions.[27]
3. Administer Oral Carbohydrates: Once the patient is awake, alert, and able to swallow safely, they must be given a fast-acting source of sugar (e.g., fruit juice, non-diet soda) to begin raising blood glucose levels. This should be followed by a longer-acting source of carbohydrates and protein (e.g., crackers with cheese or peanut butter, a sandwich) to replenish the liver's depleted glycogen stores and prevent a relapse into hypoglycemia.[27]
4. Inform Healthcare Provider: The patient's primary diabetes care provider should be notified of the severe hypoglycemic event.[64]

Table 2: Dosing Guidelines for Severe Hypoglycemia Across Formulations

Product Name (Brand)	Formulation/Route	Adult Dose (≥12 years or specific weight)	Pediatric Dose (Age 4 to <12 years)	Pediatric Dose (Age 2 to <4 years)	Key Dosing Notes
Glucagon Emergency Kit / GlucaGen HypoKit	Lyophilized Powder / IM, Sub-Q	1 mg	1 mg if ≥20-25 kg; 0.5 mg if <20-25 kg	0.5 mg	Dosing is weight-dependent for children.
Baqsimi	Nasal Powder / Intranasal	3 mg	3 mg	Not Approved	Fixed 3 mg dose for all patients ≥4 years old.
Gvoke	Liquid Solution / Sub-Q	1 mg	1 mg if ≥45 kg; 0.5 mg if <45 kg	0.5 mg	Dosing is weight-dependent for children <12 years.
Zegalogue	Liquid Solution / Sub-Q	0.6 mg	0.6 mg	Not Approved	Fixed 0.6 mg dose for all patients ≥6 years old.

Data compiled from sources:.[4]

---

Section 8: Comprehensive Safety Profile

8.1. Common and Serious Adverse Reactions

The safety profile of glucagon is well-established, with adverse reactions that are generally transient and manageable. However, the profile can differ slightly based on the formulation and route of administration.

• Common Adverse Reactions: Across all formulations, the most frequently reported adverse events are gastrointestinal in nature, specifically nausea and vomiting.[68] The incidence of nausea can be as high as 45-57% in some studies.[71] Headache is also a common side effect.[68]
• Formulation-Specific Adverse Reactions:
• Injectable Formulations (Gvoke, Zegalogue): In addition to nausea and vomiting, injection site reactions are common, including pain, edema (swelling), erythema (redness), and discomfort.[68]
• Intranasal Formulation (Baqsimi): The adverse event profile is dominated by local upper respiratory tract symptoms. These include nasal discomfort, nasal congestion, rhinorrhea (runny nose), sneezing, watery eyes (lacrimation), redness of the eyes, and itching of the nose, eyes, and throat.[68]
• Serious Adverse Reactions: While rare, serious hypersensitivity reactions have been reported with glucagon products. These can range from a generalized rash to life-threatening anaphylactic shock, characterized by breathing difficulties and hypotension.[20] Any patient with a known prior hypersensitivity to glucagon or its excipients should not use the product.

8.2. Absolute Contraindications: Pheochromocytoma and Insulinoma

There are two absolute contraindications for the use of glucagon, stemming from its potential to dangerously exacerbate the underlying pathophysiology of specific endocrine tumors.

• Pheochromocytoma: This is a rare tumor of the adrenal medulla that secretes excessive amounts of catecholamines (epinephrine and norepinephrine). Glucagon is strictly contraindicated in patients with known or suspected pheochromocytoma because it can directly stimulate the tumor to release a massive surge of these catecholamines. This can precipitate a hypertensive crisis, a rapid and severe increase in blood pressure that can be life-threatening.[20]
• Insulinoma: This is a tumor of the pancreatic beta cells that autonomously secretes large amounts of insulin, leading to recurrent and severe hypoglycemia. Glucagon is contraindicated in these patients because its administration can lead to a paradoxical and dangerous worsening of hypoglycemia. While glucagon will initially cause a transient rise in blood glucose, this hyperglycemia acts as a potent stimulus for the insulinoma, triggering an exaggerated and uncontrolled release of insulin. The result is a profound rebound hypoglycemia that can be more severe than the initial state.[19]

8.3. Warnings, Precautions, and Management of At-Risk Populations

• Lack of Efficacy in Glycogen-Depleted States: Glucagon's mechanism of action is entirely dependent on the presence of adequate glycogen stores in the liver. Therefore, it will be ineffective in patients whose glycogen stores are depleted. This includes individuals in states of prolonged starvation, those with adrenal insufficiency, or patients with chronic, long-standing hypoglycemia. In these clinical situations, the patient must be treated directly with an exogenous source of glucose (orally or intravenously).[19]
• Necrolytic Migratory Erythema (NME): NME is a distinctive, erosive skin rash that has been reported in postmarketing surveillance. It is primarily associated with glucagonomas (glucagon-producing tumors) and has also been observed in patients receiving continuous infusions of glucagon.[20] Since rescue glucagon products are not approved for continuous infusion, this is a rare consideration, but clinicians should be aware of the association.
• Patients with Cardiac Disease: Caution is advised when using glucagon as a diagnostic aid in patients with known cardiac disease. Glucagon can increase myocardial oxygen demand, blood pressure, and heart rate, which could pose a risk in this population.[20] Cardiac monitoring is recommended during such procedures.

8.4. Clinically Significant Drug-Drug Interactions

Glucagon has several clinically relevant interactions with other medications that may alter its efficacy or safety profile.

• Beta-Blockers: Patients taking beta-adrenergic blocking agents (e.g., propranolol, atenolol) may experience a transient but significant increase in both blood pressure and pulse rate upon administration of glucagon. This is because glucagon's stimulation of catecholamine release is unopposed by beta-blockade, leaving alpha-adrenergic effects to predominate.[20]
• Indomethacin: The nonsteroidal anti-inflammatory drug (NSAID) indomethacin can interfere with glucagon's ability to raise blood glucose. In patients taking indomethacin, glucagon may lose its hyperglycemic effect or, paradoxically, may even produce hypoglycemia.[20] The exact mechanism is not fully elucidated but may involve alterations in prostaglandin synthesis that affect the adenylate cyclase system.
• Warfarin: Glucagon may increase the anticoagulant effect of warfarin, potentially increasing the risk of bleeding. Patients on warfarin who receive glucagon should have their coagulation parameters (e.g., INR) monitored.[20]
• Anticholinergic Drugs: The concomitant use of anticholinergic drugs is not recommended when glucagon is being used as a diagnostic aid, as the combination may potentiate the inhibition of GI motility.[20]

Table 3: Summary of Clinically Significant Drug Interactions

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Outcome	Clinical Management/Recommendation
Beta-Blockers (e.g., propranolol, atenolol)	Glucagon stimulates catecholamine release; beta-blockade leads to unopposed alpha-adrenergic stimulation.	Transient increase in blood pressure and heart rate.	Monitor blood pressure and pulse. Use with caution.
Indomethacin	May interfere with the adenylate cyclase system, blunting glucagon's effect on the liver.	Loss of hyperglycemic effect or potential for paradoxical hypoglycemia.	Monitor blood glucose closely. Be prepared to administer glucose if glucagon is ineffective.
Warfarin	Unknown, but glucagon may potentiate the anticoagulant effect.	Increased INR and risk of bleeding.	Monitor INR if glucagon is administered to a patient on warfarin.
Anticholinergic Drugs	Additive effects on gastrointestinal smooth muscle relaxation.	Excessive inhibition of GI motility.	Concomitant use is not recommended when glucagon is used as a diagnostic aid.

Data compiled from sources:.[20]

---

Section 9: Regulatory History and Pivotal Clinical Evidence

9.1. Landmark FDA and EMA Approvals: A Historical Timeline

The regulatory history of glucagon reflects the broader evolution of pharmaceutical technology, from early approvals of basic formulations to a recent, rapid burst of innovation focused on user-centered design.

• Foundation and Early rDNA Approval: Glucagon was first approved for medical use in the United States on November 14, 1960.[8] A significant milestone was the FDA approval of Eli Lilly's Glucagon for Injection (rDNA origin) on September 11, 1998, which established recombinant DNA technology as the standard for producing high-purity, human-sequence glucagon.[22]
• The Ready-to-Use (RTU) Revolution (2019–2021): After two decades with little change in formulation, the market was transformed by the approval of three distinct RTU products in quick succession.
• Baqsimi (nasal glucagon): Eli Lilly's intranasal powder received FDA approval on July 24, 2019, becoming the first non-injectable glucagon rescue therapy.[57] The European Medicines Agency (EMA) followed with a marketing authorisation published on February 6, 2020.[77]
• Gvoke (liquid glucagon): Xeris Pharmaceuticals' stable liquid injection received FDA approval on September 10, 2019, marking the arrival of the first premixed, ready-to-use injectable.[50] It was later approved by the EMA under the brand name Ogluo on February 11, 2021.[74]
• Zegalogue (dasiglucagon): Zealand Pharma's glucagon analog injection received FDA approval on March 22, 2021, introducing a new molecular entity designed for stability.[56] The EMA granted marketing authorisation on July 24, 2024.[80]
• The First Generic Approval: A pivotal regulatory event occurred on December 28, 2020, when the FDA approved the first generic version of glucagon for injection. This product, manufactured via chemical peptide synthesis, was deemed equivalent to the recombinant innovator product, setting a key precedent for future generic peptide drugs.[1]

Table 4: Regulatory Approval Timeline for Key Glucagon Products

Date	Regulatory Body	Product Name (Brand)	Company	Key Event/Milestone
Nov 14, 1960	FDA	Glucagon	Eli Lilly	First approval for medical use in the U.S.
Sep 11, 1998	FDA	Glucagon for Injection	Eli Lilly	Approval of recombinant DNA (rDNA) origin product.
Jul 24, 2019	FDA	Baqsimi	Eli Lilly	First non-injectable, intranasal powder approved.
Sep 10, 2019	FDA	Gvoke	Xeris Pharmaceuticals	First ready-to-use, stable liquid injectable approved.
Feb 6, 2020	EMA	Baqsimi	Eli Lilly	European marketing authorisation for nasal powder.
Dec 28, 2020	FDA	Glucagon for Injection	Amphastar	First generic glucagon (synthetic peptide) approved.
Feb 11, 2021	EMA	Ogluo (Gvoke)	Xeris Pharmaceuticals	European marketing authorisation for liquid injectable.
Mar 22, 2021	FDA	Zegalogue	Zealand Pharma	First glucagon analog approved.
Jul 24, 2024	EMA	Zegalogue	Zealand Pharma	European marketing authorisation for glucagon analog.

Data compiled from sources:.[8]

9.2. Analysis of Pivotal Trials for Baqsimi (Nasal Glucagon)

The efficacy and safety of Baqsimi were established in randomized, open-label studies comparing a single 3 mg intranasal dose to a standard 1 mg intramuscular (IM) glucagon injection in patients with diabetes who had insulin-induced hypoglycemia.[82]

• Adult Studies: In pivotal trials (e.g., IGBC), Baqsimi demonstrated non-inferiority to IM glucagon. Treatment success, defined as an increase in plasma glucose to ≥70 mg/dL or an increase of ≥20 mg/dL from the glucose nadir within 30 minutes, was achieved in 98.8% to 100% of patients treated with Baqsimi, compared to 100% of those receiving IM glucagon.[25] The mean time to achieve this success was slightly longer for Baqsimi in one study (11.6 minutes vs. 9.9 minutes for IM glucagon), but this difference was not considered clinically significant.[25]
• Pediatric Study: In a study involving children and adolescents aged 4 to <17 years (IGBB), Baqsimi was also highly effective. Treatment success was achieved in 100% of pediatric patients in both the Baqsimi and IM glucagon arms, with comparable mean times to success across different age cohorts (e.g., 10.8 minutes for both treatments in children aged 4 to <8 years).[82]

9.3. Analysis of Pivotal Trials for Gvoke (Liquid Injectable Glucagon)

Gvoke's approval was based on multicenter, randomized, controlled, non-inferiority studies comparing its efficacy and safety to traditional glucagon emergency kits (GEK) that require reconstitution.[72]

• Adult Studies: In two pivotal trials (Study A and Study B) in adults with type 1 diabetes, Gvoke was shown to be non-inferior to GEK. Treatment success rates were 99% to 100% for Gvoke, compared to 100% for GEK.[47] A pooled analysis of these studies found the mean time to treatment success was 13.8 minutes.[72]
• Pediatric Study: A Phase 3 trial in pediatric patients aged 2 to <17 years with type 1 diabetes (Study C) also demonstrated high efficacy, with 100% of patients achieving the target glucose increase of ≥25 mg/dL.[47]
• Usability Studies: Crucially, human factors studies simulating a rescue situation demonstrated that caregivers and patients had a 99% success rate in correctly administering a full dose of glucagon using the simple two-step process of the Gvoke PFS and HypoPen, validating its user-friendly design.[47]

9.4. Efficacy and Safety Data for Zegalogue (Dasiglucagon)

Zegalogue was evaluated in pivotal trials comparing its efficacy to placebo in reversing insulin-induced hypoglycemia in adults and pediatric patients with type 1 diabetes.[56]

• Efficacy vs. Placebo: In both adult (Trials A and B) and pediatric (Trial C) populations, Zegalogue was vastly superior to placebo. The median time to plasma glucose recovery (defined as an increase of ≥20 mg/dL from nadir) was consistently around 10 minutes for patients receiving Zegalogue. In contrast, the median time to recovery for patients receiving placebo was significantly longer, at 30 to 40 minutes.[56] This demonstrated a rapid and statistically significant treatment effect. The safety profile was consistent with the glucagon class, with nausea and vomiting being the most common adverse events.[56]

---

Section 10: Comparative Analysis of Modern Ready-to-Use Formulations

While no direct head-to-head clinical trials have been conducted among the three novel RTU glucagon formulations (Baqsimi, Gvoke, and Zegalogue), a systematic literature review and indirect treatment comparison (ITC) of their respective pivotal trials provides valuable data for a comparative assessment.[49]

10.1. Efficacy Comparison: Time to Glucose Recovery and Treatment Success Rates

All three RTU products have demonstrated exceptionally high rates of treatment success, with over 98% of patients in clinical trials successfully reversing insulin-induced hypoglycemia.[49] This establishes that, from a primary efficacy standpoint, all three are highly reliable rescue therapies and are comparable to each other and to the traditional reconstituted glucagon standard.

Subtle differences may exist in the speed of recovery. One Bayesian ITC that included ten clinical trials found that in a combined analysis of adults with type 1 and type 2 diabetes, Baqsimi was associated with a statistically significantly faster mean time to treatment success compared to Gvoke (13.96 minutes vs. 14.66 minutes).[49] While statistically significant, the clinical relevance of a sub-one-minute difference in a non-inferiority trial context is debatable, and all products provide rapid recovery well within the critical 15-minute window.

10.2. Pharmacodynamic Distinctions: Peak Glucose Concentration and Rebound Hyperglycemia

A more pronounced and potentially clinically significant difference among the RTU formulations lies in their pharmacodynamic profiles, specifically the peak blood glucose concentration achieved after administration. The ITC revealed that Baqsimi administration resulted in a statistically significantly lower mean maximum blood glucose level (168 mg/dL) in adults compared to both Gvoke (220 mg/dL) and Zegalogue (190 mg/dL).[49]

This finding has important implications for modern diabetes management. Current clinical practice guidelines from bodies like the Endocrine Society emphasize the importance of avoiding the overtreatment of hypoglycemia to prevent subsequent rebound hyperglycemia.[85] A rescue therapy that effectively resolves hypoglycemia while producing a more modest glucose peak may be advantageous, as it could facilitate a smoother re-establishment of euglycemia and reduce the metabolic "roller coaster" effect for the patient. Therefore, the lower peak glucose associated with Baqsimi may represent a favorable pharmacodynamic characteristic.

10.3. Safety and Tolerability: A Head-to-Head Look at Adverse Event Profiles

The overall safety profiles of the three RTU products are consistent with the known effects of glucagon, with nausea and vomiting being the most common systemic side effects. The ITC found a trend towards a lower incidence of treatment-emergent adverse events (TEAEs) with Baqsimi compared to Gvoke or Zegalogue, although this difference did not reach statistical significance.[49]

The primary distinction in tolerability relates to the route of administration. The choice between products involves a trade-off between local adverse events. Baqsimi is associated with transient, local upper respiratory symptoms like nasal congestion, watery eyes, and nasal discomfort.[73] Gvoke and Zegalogue, being injectable, are associated with injection site reactions such as pain, swelling, and redness, and may have a higher incidence of systemic nausea and vomiting compared to the nasal route.[69]

10.4. Human Factors and Usability: The Clinical Impact of Simplified Administration

The most significant and universally acknowledged advantage of all three RTU formulations is the profound improvement in usability over the legacy reconstitution kits.[26] The multi-step process required for the old kits is a known barrier to successful administration, especially for untrained caregivers in an emergency.[26] By eliminating the need for reconstitution, Baqsimi, Gvoke, and Zegalogue drastically reduce the cognitive load, the number of steps, and the potential for critical errors during a rescue attempt.

This improvement is so impactful that the 2022 Endocrine Society clinical practice guideline for managing individuals at high risk for hypoglycemia explicitly recommends the use of glucagon preparations that do not require reconstitution over those that do.[26] The rationale cited is the enhanced ease of use and the avoidance of dosing errors, which directly translates to more rapid and reliable treatment of severe hypoglycemia in an outpatient setting.[26] This recommendation effectively establishes RTU formulations as the new standard of care.

Table 5: Comparative Efficacy and Safety of Ready-to-Use Glucagon Formulations (from Clinical Trials)

Parameter	Baqsimi (nasal glucagon)	Gvoke (liquid glucagon)	Zegalogue (dasiglucagon)	Data Source/Citation
Treatment Success Rate (Adults)	>98.8%	>99%	>99% (vs. Placebo)	25
Mean Time to Success (Adults)	~11.6 - 14.0 min	~13.8 - 14.7 min	~10 min (vs. Placebo)	25
Mean Max. Blood Glucose (Adults)	168 mg/dL	220 mg/dL	190 mg/dL	49
Most Common Adverse Events (Adults)	Nausea, Vomiting, Headache, Upper Respiratory Irritation	Nausea (30%), Vomiting (16%), Injection Site Edema (7%), Headache (5%)	Nausea (57%), Vomiting (25%), Headache (11%), Diarrhea (5%)	69
Most Common Adverse Events (Pediatrics)	Vomiting (31%), Headache (25%), Nausea (17%), Upper Resp. Irritation (17%)	Nausea (45%), Hypoglycemia (39%), Vomiting (19%), Headache (7%)	Nausea (65%), Vomiting (50%), Headache (10%)	69

Note: Data is compiled from pivotal trials and indirect treatment comparisons. Direct head-to-head trial data is not available. Time to success definitions and study populations may vary slightly between trials.

---

Section 11: Conclusion and Future Perspectives

11.1. Synthesis of Key Findings: The New Standard of Care for Severe Hypoglycemia

The journey of glucagon as a therapeutic agent is a compelling narrative of scientific and technological progress. From its origins as an impure animal extract, it has evolved into a highly purified, human-sequence hormone produced through sophisticated biosynthetic methods. The recent era of innovation has culminated in a paradigm shift in the management of severe hypoglycemia. The introduction of stable, ready-to-use formulations—Baqsimi, Gvoke, and Zegalogue—has effectively rendered the cumbersome and error-prone reconstitution kit obsolete for most outpatient settings.

These novel products have demonstrated high efficacy, safety, and, most importantly, superior usability. By simplifying or eliminating steps, reducing the cognitive burden on caregivers, and offering needle-free options, they ensure that this life-saving treatment can be delivered more rapidly and reliably during a crisis. The explicit recommendation from the Endocrine Society in favor of RTU formulations solidifies their position as the new standard of care.[26] While all are highly effective, the choice among them may be guided by nuanced differences in pharmacodynamic profiles, patient age, and individual or caregiver preference for an intranasal versus an injectable route of administration.

11.2. Unmet Needs and the Future of Glucagon Therapy

Despite these remarkable advances in rescue therapy, a significant unmet need remains: the proactive prevention of hypoglycemia. The ultimate goal in glucagon research is the development of an ultrastable, soluble glucagon formulation that is suitable for long-term, continuous subcutaneous infusion in a bi-hormonal artificial pancreas system.[21] Such a system would pair an insulin pump with a glucagon pump, all controlled by a continuous glucose monitor and a sophisticated algorithm. It would not only deliver insulin to manage hyperglycemia but also administer precise micro-boluses of glucagon to counteract impending hypoglycemia before it becomes severe.

The primary obstacle to this vision has always been the inherent instability of the native glucagon molecule.[29] Current research is intensely focused on overcoming this challenge through several innovative approaches:

• Novel Analogs: Creating new molecular versions of glucagon with amino acid substitutions that enhance stability without compromising receptor activity, similar to the approach used for dasiglucagon.[6]
• Fusion Proteins: Engineering single molecules that combine glucagon with another peptide, such as insulin or GLP-1, to create a bi-functional agent with unique properties or improved stability.[21]
• Advanced Formulations: Exploring novel excipients, solvents, or molecular modifications like glycosylation to prevent fibrillation and degradation in aqueous solutions, allowing for long-term stability in a pump reservoir.[9]

11.3. Final Recommendations for Clinical Practice and Research

Based on the comprehensive analysis presented in this report, the following recommendations are put forth:

• For Clinical Practice: Healthcare providers should prioritize prescribing RTU glucagon formulations for all patients at risk of severe hypoglycemia, in line with current expert guidelines. A critical component of this prescription must be thorough education for both patients and their designated caregivers on the recognition of severe hypoglycemia and the correct and prompt use of their specific rescue device.
• For Clinical Research: There is a clear need for direct, head-to-head, randomized controlled trials to definitively compare the efficacy, safety, and human factors performance of the available RTU glucagon products (Baqsimi, Gvoke, and Zegalogue). Continued investment and focus on the development of stable glucagon formulations for use in bi-hormonal closed-loop systems should be a top priority, as this represents the next frontier in achieving near-normal glycemic control and reducing the burden of hypoglycemia in diabetes management.
• For Payers and Health Systems: The significant advantages of RTU formulations in reducing administration errors and improving the likelihood of a successful rescue should be recognized in formulary and coverage decisions. While the acquisition cost may be higher than for older kits, the potential to prevent costly emergency room visits and hospitalizations associated with failed or delayed treatment for severe hypoglycemia represents a significant long-term value proposition.

Works cited

1. Glucagon API Manufacturer & Supply - Bachem, accessed August 23, 2025, https://www.bachem.com/all-generic-apis/glucagon/
2. CA1294232C - Process for preparing glucagon or derivatives or fragments thereof in yeast - Google Patents, accessed August 23, 2025, https://patents.google.com/patent/CA1294232C/en
3. Glucagon (1-29), Human - GenScript, accessed August 23, 2025, https://www.genscript.com/peptide/RP10772-Glucagon_1_29_Human.html
4. glucagon for injection - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201849s013lbl.pdf
5. GLUCAGON FOR INJECTION - accessdata.fda.gov, accessed August 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020928s055lbl.pdf
6. Optimization of the Native Glucagon Sequence for Medicinal Purposes - PMC, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3005041/
7. Glucagon rescue - Wikipedia, accessed August 23, 2025, https://en.wikipedia.org/wiki/Glucagon_rescue
8. Glucagon (medication) - Wikipedia, accessed August 23, 2025, https://en.wikipedia.org/wiki/Glucagon_(medication)
9. Total Chemical Synthesis of Glucagon Glycoforms Reveals the Remarkable Influence of Natural Glycosylation - ACS Publications, accessed August 23, 2025, https://pubs.acs.org/doi/10.1021/jacs.5c03757
10. New uses and formulations of glucagon for hypoglycaemia - PMC - PubMed Central, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6675539/
11. The Physiology of Glucagon - PMC - PubMed Central, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3005043/
12. Glucagon-like peptide-1 - Wikipedia, accessed August 23, 2025, https://en.wikipedia.org/wiki/Glucagon-like_peptide-1
13. The New Biology and Pharmacology of Glucagon | Physiological Reviews, accessed August 23, 2025, https://journals.physiology.org/doi/10.1152/physrev.00025.2016
14. Glucagon biosynthesis, accessed August 23, 2025, https://www.glucagon.com/glucagon.html
15. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes - PubMed, accessed August 23, 2025, https://pubmed.ncbi.nlm.nih.gov/15852457/
16. Glucagon Physiology - Endotext - NCBI Bookshelf, accessed August 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK279127/
17. Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes - Frontiers, accessed August 23, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.928016/full
18. Glucagon: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 23, 2025, https://go.drugbank.com/drugs/DB00040
19. BAQSIMI (glucagon) nasal powder - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf
20. GlucaGon (Glucagon for Injection): Side Effects, Uses, Dosage, Interactions, Warnings, accessed August 23, 2025, https://www.rxlist.com/glucagon-drug.htm
21. Ultrastable Insulin-Glucagon Fusion Protein Exploits an Endogenous Hepatic Switch to Mitigate Hypoglycemic Risk | ACS Pharmacology & Translational Science, accessed August 23, 2025, https://pubs.acs.org/doi/10.1021/acsptsci.5c00362
22. Untitled - accessdata.fda.gov, accessed August 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20928.pdf
23. Glucagon - StatPearls - NCBI Bookshelf, accessed August 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK559195/
24. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GLUCAGON FOR INJECTION, accessed August 23, 2025, https://www.glucagonemergencykit.com/wp-content/uploads/2019/11/NDA-201849_005_PI-S_9_9_19_FINAL1.pdf
25. Adult Clinical Trials - Baqsimi, accessed August 23, 2025, https://www.baqsimi.com/health-care-providers/adult/clinical-trials/
26. Glucagon Agents Summary, accessed August 23, 2025, https://www.hhs.texas.gov/sites/default/files/documents/jan-2024-durb-agenda-item5l.pdf
27. Glucagon (injection route) - Side effects & dosage - Mayo Clinic, accessed August 23, 2025, https://www.mayoclinic.org/drugs-supplements/glucagon-injection-route/description/drg-20064089
28. Glucagon Patient Tips: 7 things you should know - Drugs.com, accessed August 23, 2025, https://www.drugs.com/tips/glucagon-patient-tips
29. Researchers Formulate Stable Liquid Glucagon - Kansas and Missouri Chapter, accessed August 23, 2025, https://www.breakthrought1d.org/kansasmissouri/2012/11/16/researchers-formulate-stable-liquid-glucagon/
30. WO2020254479A1 - Process for the manufacture of glucagon - Google Patents, accessed August 23, 2025, https://patents.google.com/patent/WO2020254479A1/en
31. Scientific and Regulatory Considerations for the Approval of the First ..., accessed August 23, 2025, https://academic.oup.com/jes/article/5/Supplement_1/A324/6240767
32. Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon, accessed August 23, 2025, https://www.researchgate.net/publication/353140287_Scientific_and_Regulatory_Considerations_for_the_Approval_of_the_First_Generic_Glucagon
33. Glucagon - USP-NF ABSTRACT, accessed August 23, 2025, https://doi.usp.org/USPNF/USPNF_M35160_05_01.html
34. Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions - MDPI, accessed August 23, 2025, https://www.mdpi.com/2218-0532/90/2/32
35. Comparison of Yeasts as Hosts for Recombinant Protein Production - PMC, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6027275/
36. Yeasts as Biopharmaceutical Production Platforms - PMC - PubMed Central, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10512354/
37. Recombinant glucagon: a differential biological activity - PMC, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4385203/
38. Why GLP-1 Manufacturing Needs a New Biopharma Approach - News-Medical, accessed August 23, 2025, https://www.news-medical.net/life-sciences/Why-GLP-1-Manufacturing-Needs-a-New-Biopharma-Approach.aspx
39. A Proficient Approach to the Production of Therapeutic Glucagon-Like Peptide-1 (GLP-1) in Transgenic Plants - The Open Biotechnology Journal, accessed August 23, 2025, https://openbiotechnologyjournal.com/VOLUME/3/PAGE/57/PDF/
40. Yeast synthetic biology for the production of recombinant therapeutic proteins, accessed August 23, 2025, https://academic.oup.com/femsyr/article-pdf/15/1/1/10745568/12195.pdf
41. Synthetic Manufacturing of Glucagon - Thomas Meier - YouTube, accessed August 23, 2025, https://www.youtube.com/watch?v=5XxvI3vgWQA
42. The Technologies Propelling GLP-1 Analogues - Drug Delivery Leader, accessed August 23, 2025, https://www.drugdeliveryleader.com/doc/the-technologies-propelling-glp-analogues-0001
43. The FDA-approved Glucagon Emergency Kit from Fresenius Kabi is a cost-effective alternative to emergency solutions you have trusted for years., accessed August 23, 2025, https://www.glucagonemergencykit.com/wp-content/uploads/2019/11/Glucagon_Sales_Aid_WEB_VERSION_191211.pdf
44. Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions - DOAJ, accessed August 23, 2025, https://doaj.org/article/3ee7dcd6eb55469f92ed8151eba182ac
45. (PDF) Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions - ResearchGate, accessed August 23, 2025, https://www.researchgate.net/publication/360661585_Comparison_of_the_Purity_and_Impurity_of_Glucagon-for-Injection_Products_under_Various_Stability_Conditions
46. Product Information - Baqsimi, accessed August 23, 2025, https://www.baqsimi.com/product-information/
47. Gvoke | Xeris Biopharma Holdings, Inc., accessed August 23, 2025, https://xerispharma.com/products/gvoke/
48. When to use BAQSIMI, accessed August 23, 2025, https://www.baqsimi.com/when-to-use-baqsimi/
49. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10570215/
50. Gvoke (glucagon) FDA Approval History - Drugs.com, accessed August 23, 2025, https://www.drugs.com/history/gvoke.html
51. Glucagon Monograph for Professionals - Drugs.com, accessed August 23, 2025, https://www.drugs.com/monograph/glucagon.html
52. Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia - PMC, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6794225/
53. Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia | Xeris Biopharma Holdings, Inc., accessed August 23, 2025, https://investors.xerispharma.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon/
54. 2019 Nov 18 (1585): In Brief: A New Glucagon Injection (Gvoke) for Severe Hypoglycemia - The Medical Letter, accessed August 23, 2025, https://secure.medicalletter.org/system/files/private/TML-article-1585d.pdf
55. These highlights do not include all the information needed to use GVOKE and GVOKE VialDx safely and effectively. See full prescribing information for GVOKE and GVOKE VialDx. GVOKE (glucagon) injection, for subcutaneous useGVOKE VialDx (glucagon) injection, for intravenous useInitial U.S. Approval: 1960 - DailyMed, accessed August 23, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=92385737-dbad-98c5-e053-2995a90a2805
56. Drug Trials Snapshots: ZEGALOGUE - FDA, accessed August 23, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zegalogue
57. Gvoke | The Medical Letter Inc., accessed August 23, 2025, https://secure.medicalletter.org/taxonomy/term/16007
58. How Do Zegalogue vs Glucagon Work for Hypoglycemia Treatment? - GoodRx, accessed August 23, 2025, https://www.goodrx.com/conditions/hypoglycemia/zegalogue-vs-glucagon-for-severe-low-blood-sugar
59. Baqsimi (glucagon) FDA Approval History - Drugs.com, accessed August 23, 2025, https://www.drugs.com/history/baqsimi.html
60. Adult Patients - Baqsimi, accessed August 23, 2025, https://www.baqsimi.com/health-care-providers/adult/
61. Label: GLUCAGON kit - DailyMed, accessed August 23, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b49500-0aae-4e25-9a1d-709983233cc6
62. GVOKE (glucagon) injection, for subcutaneous use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 23, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212097s000lbl.pdf
63. Zegalogue® (dasiglucagon), accessed August 23, 2025, https://www.lablue.com/-/media/Medical%20Policies/2021/12/12/19/54/Zegalogue%20dasiglucagon%2000764%2020211213_accessible%20pdf.pdf
64. How to Use a Glucagon Emergency Kit | Cincinnati Children's - YouTube, accessed August 23, 2025, https://www.youtube.com/watch?v=cHuyxbYG26g
65. How To Use an Emergency Glucagon Injection Kit | Memorial Sloan Kettering Cancer Center, accessed August 23, 2025, https://www.mskcc.org/cancer-care/patient-education/glucagon-emergency-kit-low-blood-sugar-glucagon-injection
66. Instructions for Use - Glucagon Emergency Kit, accessed August 23, 2025, https://www.glucagonemergencykit.com/instructions-for-use/
67. How to Use Glucagon | ADA - American Diabetes Association, accessed August 23, 2025, https://diabetes.org/living-with-diabetes/hypoglycemia-low-blood-glucose/how-use-glucagon
68. Baqsimi Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 23, 2025, https://www.drugs.com/sfx/baqsimi-side-effects.html
69. gvoke-prescribing-information.pdf - Gvoke HypoPen® (glucagon ..., accessed August 23, 2025, https://www.gvokeglucagon.com/wp-content/uploads/2023/07/gvoke-prescribing-information.pdf
70. Zegalogue Autoinjector Uses, Side Effects & Warnings - Drugs.com, accessed August 23, 2025, https://www.drugs.com/mtm/zegalogue-autoinjector.html
71. Zegalogue (dasiglucagon): Uses, Alternatives, FAQs & More - GoodRx, accessed August 23, 2025, https://www.goodrx.com/zegalogue/what-is
72. Demonstrated Efficacy | Gvoke® (glucagon injection), accessed August 23, 2025, https://www.gvokeglucagon.com/hcp/about-gvoke
73. Important Safety Information - Baqsimi, accessed August 23, 2025, https://www.baqsimi.com/safety-information/
74. Xeris Pharmaceuticals Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke® Kit for the Treatment of Severe Hypoglycemia, accessed August 23, 2025, https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-announces-approval-supplemental-new-drug/
75. Zegalogue (dasiglucagon): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed August 23, 2025, https://www.webmd.com/drugs/2/drug-181193/zegalogue-autoinjector-subcutaneous/details
76. Zegalogue (dasiglucagon) dosing, indications, interactions, adverse effects, and more, accessed August 23, 2025, https://reference.medscape.com/drug/zegalogue-dasiglucagon-4000161
77. Baqsimi | European Medicines Agency (EMA), accessed August 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/baqsimi
78. Generic Gvoke Availability - Drugs.com, accessed August 23, 2025, https://www.drugs.com/availability/generic-gvoke.html
79. EMA backs Xeris' ready-to-use glucagon for approval, setting up showdown with Novo and Lilly | Fierce Pharma, accessed August 23, 2025, https://www.fiercepharma.com/drug-delivery/ema-backs-xeris-ready-to-use-glucagon-for-approval-setting-up-showdown-novo-and-lilly
80. In which countries is Dasiglucagon approved? - Patsnap Synapse, accessed August 23, 2025, https://synapse.patsnap.com/article/in-which-countries-is-dasiglucagon-approved
81. Zegalogue | European Medicines Agency (EMA), accessed August 23, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/zegalogue
82. Executive Summary - Clinical Review Report: Glucagon Nasal Powder (Baqsimi) - NCBI, accessed August 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK563001/
83. Pediatric Clinical Trials - Baqsimi, accessed August 23, 2025, https://www.baqsimi.com/health-care-providers/pediatrics/clinical-trials/
84. Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar, accessed August 23, 2025, https://www.gvokeglucagon.com/
85. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia - ResearchGate, accessed August 23, 2025, https://www.researchgate.net/publication/373931231_Systematic_Literature_Review_and_Indirect_Treatment_Comparison_of_Three_Ready-to-Use_Glucagon_Treatments_for_Severe_Hypoglycemia
86. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia - PubMed, accessed August 23, 2025, https://pubmed.ncbi.nlm.nih.gov/37707700/
87. Glucagon Agents, accessed August 23, 2025, https://www.hhs.texas.gov/sites/default/files/documents/january-2025-durb-agenda-item4l.pdf
88. What are the differences among available glucagon preparations? - Dr.Oracle AI, accessed August 23, 2025, https://www.droracle.ai/articles/148251/are-there-any-differences-in-glucagon-amongst-the-available-preparations
89. A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection - PubMed Central, accessed August 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3834218/
90. Glucagon Interactions Checker - Drugs.com, accessed August 23, 2025, https://www.drugs.com/drug-interactions/glucagon.html